11.4 Direct Antiglobulin Testing & Reagents

11.4 Direct Antiglobulin Testing & Reagents

SBB Focus: The DAT tells you what is already stuck to the patient's red cells in vivo; the antibody screen (IAT) tells you what is floating free in the patient's plasma. Confusing the two, or misreading which AHG reagent produced a result, is one of the most common specialist-level errors this section is designed to catch.

Principle: DAT vs. IAT

The direct antiglobulin test (DAT) detects red cells already coated with IgG and/or complement (C3d) in the patient's circulation — no incubation step is needed because the sensitization already happened in vivo. This is fundamentally different from the indirect antiglobulin test (IAT) used in antibody screening and crossmatching, which detects antibody free in serum or plasma by incubating it with reagent or donor cells in vitro.

Polyspecific vs. Monospecific Reagents

Polyspecific AHG reagent contains both anti-IgG and anti-complement (anti-C3d) activity and is used as the initial screening test. If the polyspecific DAT is positive, monospecific reagents — anti-IgG alone and anti-C3d alone — are run separately to determine exactly which coating component is present, which drives the differential diagnosis.

Reading the Pattern

AHG Reagent Quality Control: Check Cells

Every negative AHG test — whether an antibody screen, crossmatch, or DAT — must be validated with check cells (IgG-sensitized reagent red cells, also called Coombs control cells). Adding check cells to a negative tube and seeing at least 1+ agglutination confirms that reactive AHG reagent was actually added, was not neutralized by residual serum protein, and reached the cells. If check cells fail to react, the "negative" result is invalid and the entire test must be repeated from the beginning — a negative result that is never validated cannot be reported as negative.

False-Negative Causes

• Inadequate washing is the single most common cause: leftover serum globulins neutralize the AHG reagent before it can reach antibody-coated cells.
• Delay between washing and AHG addition, allowing a weak or low-affinity antibody to dissociate from the cell before the reagent is added.
• Under-centrifugation or an incorrectly prepared cell suspension, whether too heavy or too light.
• Wrong anticoagulant for complement-dependent testing — samples should be collected in EDTA when complement activity matters, since EDTA chelates calcium and prevents in vitro complement activation and consumption that could otherwise mask a true C3d-mediated reaction.

False-Positive Causes

Over-centrifugation, bacterial contamination of the specimen, cold agglutinins reacting before the AHG phase is reached, Wharton's jelly contamination producing polyagglutination-like reactivity in cord blood samples, and in vitro complement activation in a refrigerated clotted sample can all mimic a true positive.

Mixed-Field Reactions in Recently Transfused Patients

A recently transfused patient carries two red cell populations: their own native cells and the donor's transfused cells. If the patient has an untreated warm autoimmune process or is experiencing a delayed hemolytic transfusion reaction, only one of those populations may be coated with antibody, producing a mixed-field DAT — a mixture of agglutinated and free, unagglutinated cells in the same tube rather than a uniform reaction. Mixed-field DAT results should prompt a review of transfusion timing before the pattern is assumed to represent partial or weak antibody coating; in a delayed hemolytic transfusion reaction, the transfused donor cells are typically the population being destroyed, while the patient's own cells remain unaffected.

Drug-Induced Immune Hemolytic Anemia Mechanisms

Drug-induced immune hemolytic anemia (DIIHA) produces DAT patterns that mimic other conditions and must be distinguished by medication history. Three classic mechanisms are recognized: the drug adsorption (hapten) mechanism, in which a drug such as high-dose penicillin binds tightly to the red cell membrane and antibody forms against the drug-coated cell — the DAT is IgG-positive, and the eluate reacts only against drug-treated reagent cells, not untreated ones. The immune complex mechanism, historically associated with drugs like certain cephalosporins and quinidine, involves an antibody-drug complex that loosely attaches to the red cell membrane and activates complement — the DAT is typically C3d-positive, and the eluate is often nonreactive because the causative complex dissociates during testing. The drug-independent (autoantibody induction) mechanism, associated with drugs such as fludarabine and historically methyldopa, triggers true autoantibody production that is serologically indistinguishable from warm autoimmune hemolytic anemia — the DAT is IgG-positive and the eluate reacts against all normal reagent cells regardless of drug exposure. Correlating the DAT pattern, eluate reactivity, and a current medication list is often the only way to separate a drug-induced process from primary autoimmune hemolytic anemia.

Eluate Testing After a Positive DAT

When the DAT is IgG-positive, an eluate — prepared by heat, acid, or another elution method to strip antibody off the red cell membrane — is tested against a full antibody identification panel. This step can confirm a warm autoantibody, uncover an underlying alloantibody masked by autoantibody, or identify the causative antibody in a hemolytic transfusion reaction or HDFN workup. Eluate testing is often the only way to see a clinically important alloantibody that is completely hidden by a strongly reactive autoantibody in the unadsorbed serum.